Recipharm Secures Financing for Future Growth
News May 23, 2012
Recipharm has announced that it has arranged a five-year loan facility with Swedbank AB (publ), one of the largest banks in Sweden.
The total loan facility of Euro 90 million will serve as an additional resource to facilitate future expansion plans set in place for the business, especially in the field of contract pharmaceutical development.
The funds will in part be targeted at increasing capital investment into Recipharm’s existing sites and facilities to meet expanding customer demand.
The finance will also be used to bolster the next phase of the company’s rolled out programme of strategic acquisitions.
Moroever, significant resources from the loan pool will be assigned to building and enhancing existing and new customer relationships.
Thomas Eldered, CEO of Recipham AB, commented: “The new financing will serve to bolster initiatives designed to build and foster strong customer relationships with all our clients across the pharmaceuticals sector. Indeed, Recipharm adopts a partnering approach to client relations to ensure that we consistently provide bespoke services that meet the precise needs of each individual customer both now and in the future. As a forward looking enterprise, we very much want to be there for the long term whilst at the same time having the flexible and established capabilities to respond rapidly to varying and immediate customer needs. Our programme of strategic acquisitions and investment in current facilities has always been geared towards increasing and expanding the services that we tailor to each specific client. We look forward to continuing in this vein.”
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE